Detalhe da pesquisa
1.
Final analysis of 379 pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry.
Mult Scler
; 30(2): 209-215, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38166480
2.
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Mult Scler
; 28(5): 801-816, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465252
3.
Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta.
Mult Scler
; 24(13): 1725-1736, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28914581
4.
Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon ß-1a phase 1 study.
Med
; 3(9): 612-621.e3, 2022 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35853458
5.
Global Landscape of Benefit-Risk Considerations for Medicinal Products: Current State and Future Directions.
Pharmaceut Med
; 36(4): 201-213, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35780471
6.
Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies.
Front Neurol
; 13: 809273, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35370887
7.
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry.
Neurol Neuroimmunol Neuroinflamm
; 9(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34815321
8.
Effect of Dimethyl Fumarate vs Interferon ß-1a in Patients With Pediatric-Onset Multiple Sclerosis: The CONNECT Randomized Clinical Trial.
JAMA Netw Open
; 5(9): e2230439, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36169959
9.
Matching-adjusted comparisons demonstrate better clinical outcomes in patients with relapsing multiple sclerosis treated with peginterferon beta-1a than with teriflunomide.
Mult Scler Relat Disord
; 40: 101954, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32078948